Ot aborta k sokhraneniyu reproduktivnogo zdorov'ya: novoe v kontratseptsii
- Авторлар: Prilepskaya V.N1, Dovletkhanova E.R1, Abakarova P.R1
-
Мекемелер:
- Шығарылым: № 12 (2013)
- Беттер: 46-49
- Бөлім: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/282257
- ID: 282257
Дәйексөз келтіру
Ашық рұқсат
Рұқсат берілді
Аннотация
Abortion is a major hazard for women's reproductive health. Despite the fact that the situation in regard to abortions in Russia is improving, abortion level remains one of the highest in Europe and worldwide. To a large extent, this is due to the insufficient use of modern contraceptive methods. According to the data of survey presented in this article, most women prefer ineffective methods of contraception. Only about 30 % of the respondents used modern methods, most often combined oral contraceptives (COCs) and intrauterine devices. In this regard, the introduction of modern methods of contraception, including COCs, should be considered as an important step towards reproductive health and quality of life of women. The data on the new highly effective innovative COC Zoely® with estrogen and progestogen components similar to natural hormones are presented. It is a promising new generation oral contraceptive that can not only provide acceptable control of the menstrual cycle of women, but also has a certain therapeutic effect.
Негізгі сөздер
Толық мәтін
Әдебиет тізімі
- Прилепская В.Н. Руководство по контрацепции. М., 2010. 444 с.
- Прилепская В.Н. Инновации в контрацепции. Новый комбинированный оральный контрацептив (обзор литературы) // Гинекология 2012. Т. 14. № 3. С. 32-37.
- ВОЗ. Свод практических рекомендаций по применению средств контрацепции. Обновление 2008 г.
- Савельева И.С. Комбинированная оральная контрацепция как профилактика аборта и лечение его осложнений // Гинекология 2002. Т. 4. № 3. С. 107-111.
- Федеральная служба государственной статистики. Статистический сборник "Женщины и мужчины России-2010".
- WHO. Medical eligibility criteria for contraceptive use. 4th edition. Geneva, 2009.
- Gaussem P, Alhenc-Gelas M, Thomas JL, et al. Haemostatic effects of a new combined oral contraceptive, nomegestrol acetate/17/3-estradiol, compared with those of levonorgestrel/ethinyl estradiol. A double-blind, randomised study. Thromb Haemost 2011;105(3): 560-67.
- Gallo MF, Lopez LM, Grimes DA, et al. Combination contraceptives: effects on weight. Cochrane Database Syst Rev2008;1:CD003987.
- Schindler A. Classification and pharmacology of progestins. Maturitas 2008;61: 171-80.
- Mueck AO, Sitruk-Ware R. Nomegestrolacetate, a novelprogestogen for oral contraception. Steroids 2011; 76:531-39.
- Van Diepen HA, Lam TW, Kuil CW. Nomegestrol acetate: steroid receptor transactivation profile in Chinese hamster ovary cells and ovulation inhibition in rat and monkey. Contraception 2011;84:199-204.
- Zoely® summary of product characteristics. London, England: MerckSerono Europe Limited, 2011.
- Mansour D, Verhoeven C, Sommer W, et al. Efficacy and tolerability of a monophasic combined oral contraceptive containing nomegestrol acetate and 17fi-oestradiol in a 24/4 regimen, in comparison to an oral contraceptive containing ethinylestradiol and drospirenone in a 21/7 regimen. Eur J Contracept Reprod Health Care 2011;16(6):430-43.
- Wiegratz I, Hommel HH, Zimmermann T, Kuhl H. Attitude of German women and gynecologists towards long-cycle treatment with oral contraceptives. Contraception 2004;69(1):37-42.
- Yang LP, Plosker GL. Nomegestrol acetate/ estradiol: in oral contraception. Drugs 2012;72(14):1917-28.
- Christin-Maitre S, Laroche E, Bricaire L. A new contraceptive pill containing 17β-estradiol and nomegestrol acetate. Womens Health (Lond Engl) 2013;9(1):13-23.
- United Nations Population Update Report, 2009.
Қосымша файлдар
